Press Releases

Press Releases

May 12, 2021
Journal of Clinical Oncology Publishes Clinical Data for Cohort 2 in Iovance C-144-01 Study of Lifileucel TIL Therapy in Metastatic Melanoma
Median Duration of Response Not Reached at 18.7 Months of Median Study Follow Up C-144-01 Study Contributes to Advancement in TIL Therapy Using Centrally  Standardized Manufacturing, Allowing for Broadened Patient Access SAN CARLOS, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics,
May 06, 2021
Iovance Biotherapeutics Reports First Quarter 2021 Financial Results and Corporate Updates
Expanding First-in-Class TIL Cell Therapy Platform for Solid Tumors SAN CARLOS, Calif. , May 06, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
May 04, 2021
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif. , May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual conferences in May: Truist
April 28, 2021
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif. , April 28, 2021 (GLOBE NEWSWIRE) -- Iovance
April 27, 2021
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
SAN CARLOS, Calif. , April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6, 2021 .
April 09, 2021
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma During American Association for Cancer Research (AACR) 2021 Annual Meeting
Median Duration of Response Not Reached at 28.1 Months  of Median Study Follow Up in Cohort 2 of C-144-01 Study 36.4% Overall Response Rate; Continued Deepening of Responses SAN CARLOS, Calif. , April 09, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc.
March 15, 2021
Iovance Biotherapeutics Appoints Igor Bilinsky as Chief Operating Officer
SAN CARLOS, Calif. , March 15, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced the appointment of Igor Bilinsky , Ph.D., as Chief Operating Officer, effective today. Dr.
March 10, 2021
Iovance Biotherapeutics to Present Updated Clinical Data for Tumor Infiltrating Lymphocyte (TIL) Therapy Lifileucel in Advanced Melanoma at American Association for Cancer Research (AACR) 2021 Annual Meeting
SAN CARLOS, Calif. , March 10, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that long-term interim data from Cohort 2 in the C-144-01 clinical study (NCT02360579) in
March 01, 2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , March 01, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences:
February 25, 2021
Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates
Advancing First-in-Class TIL Cell Therapy for Solid Tumors SAN CARLOS, Calif. , Feb. 25, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies (tumor-infiltrating lymphocyte, TIL, and
February 18, 2021
Iovance Biotherapeutics to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call and Webcast on Thursday, February 25, 2021
SAN CARLOS, Calif. , Feb. 18, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 .
January 19, 2021
Iovance Biotherapeutics to Present at Upcoming Healthcare Conferences
SAN CARLOS, Calif. , Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the following virtual healthcare conferences: B.